← Back to SYRE

Spyre Therapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 04/08/2026Mar 2026Filed 04/08/2026Sep 2025Filed 04/11/2025Jun 2025Filed 04/08/2026Mar 2025Filed 04/08/2026Sep 2024Filed 04/11/2025Jun 2024Filed 04/11/2025Mar 2024Filed 04/11/2025
$0$0$0
−$36−$69−$11−$37−$45−$69−$39−$44
−$0.74$1.06$0.59$0.72
514537

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.